Rethinking Biotech Valuation
Redefining Pharmaceutical Research and Training with Digital Twins and AI
Microbiological QC Bottlenecks in Biopharma
Navigating the Future
TRADITIONAL PHARMA FACILITIES
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Thomson Reuters
Senior Vice President
We believe publications such as Pharmafocus Asia are essential in providing professionals with insights into the dynamic and evolving trends of the Pharma industry
Articles
Design of Self-antibacterial and Biocompatible Titanium Surfaces for Biomedical Applications
Metals and alloys are the first generation bioinert biomaterials These materials possess excellent mechanical strength low elastic modulus and good corrosion resistance Titanium Ti and its alloys are one of the commonly used metallic biomaterials for orthopedic applications eg bone plates screws dental implants and prostheses Both bulk and surface properties
Research Insights
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections
There is disagreement about the level of asymptomatic severe acute respiratory syndrome coronavirus SARSCoV infection We conducted a living systematic review and metaanalysis to address three questions Amongst people who become infected with SARSCoV what proportion does not experience symptoms at all during their infection
Case Studies
<sup>14</sup>C microtracer+Accelerator Mass Spectrometry - Xceleron Case Studies
Introduction Xceleron is a world leader in the use of Accelerator Mass Spectrometry AMS analytical technology in pharmaceutical food technology crop protection and biobased product applications Our primary business is in pharmaceutical research and development Since we have been helping to design preclinical and clinical investigations around the
Techno Trends
Cyclica Launches First-of-its-kind Ligand Design<sup>TM</sup>
Cyclica a biotechnology company announced its novel firstinclass drug design technology Ligand DesignTM at the Collision Conference in Toronto
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
There’s Finally Hope to Alleviate the Burden of Chronic Diseases
Raman Singh oversees global pharmaceutical operations at Juniper Biologics. The company focuses on researching, developing, and commercializing novel therapies in oncology, rare diseases, and gene therapy. Under his leadership, Juniper expanded operations in Asia, Middle East, and Africa. Raman also led a US$600m acquisition of TG-C (gene therapy) and acquired oncology treatments for multiple regions.
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
Synbiotics in Metabolic Health
Dr. Neeraj Mishra is working as Professor and Head, Department of Pharmaceutics, in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience. He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localised drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. Dr. Mishra more than 3700 citations with h- index 32. The total cumulative Impact Factor of his published papers is more than 300 (as per SCOPUS). He has also written 15 Books and 30 book chapters in Elsevier, Bentham, Springer and Wiley Publication etc. He has also been granted 3 international patents and 2 Indian patents. Dr. Mishra is recipient of “Distinguished Professor Award” 2019 from DST-NSTMIS, SPAICS, Indore, and M.P. in September 2019. Dr. Mishra has received the “Distinguished Professor Award '' 2021 from Indian Pharmaceutical Association, MP State Branch, Indore. Dr Mishra has received Best Academician Award in the Indian Pharmacy Graduate Association, M.P. State International Conference held on 06th May 2023 at DAVV Auditorium, Indore, India.
Dr. Devyani Rajput is working as an Assistant Professor, Department of Pharmacognosy, in Amity Institute of Pharmacy, Gwalior since Jan 2024. She has around seven years of research experience. Her expertise includes nanotechnology, phytomedicine, and advanced drug delivery systems, with notable contributions to cancer research. She has participated in various national and international conferences, published impactful research, and received prestigious awards, including the BEST SCHOLAR AWARD 2023. She has more than 150 citations with h- index 3. She has received the CSIR travel Grant in April 2024 for presenting her research work in Istanbul University.
Endocrine Disrupting Compounds (EDCs)
Sintu Kumar Samanta has been working as an Assistant professor in IIIT Allahabad, India. He did Ph.D. and post-doctoral research from IIT Kharagpur and IISc Bangalore, India respectively. He is working in the area of Biochemistry and Nanobiotechnology. He published research work in several international journals and filed one Indian patent.
Pavan Kumar Gautamis presently working as a Post-Doctoral Fellow in the Department of Applied Sciences at IIIT Allahabad, India. He obtained Ph.D. from the University of Allahabad, India. His area of research is synthesis of nanoparticles for water remediation. He published his research work in many international journals.
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
press releasesRead more...
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
Akeso Inc HK today announced that the National Medical Products Administration NMPA of China has approved gumokimab AK the companys internallydeveloped antiIL monoclonal antibody
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Roche SIX RO ROP OTCQX RHHBY announced today the European Union In Vitro Diagnostic Regulation IVDR approval of several label expansions for the VENTANA MMR RxDx Panel an immunohistochemistry
DKSH Partners with BridgeBio to Advance Regulatory Review and Potential Access to ATTR-CM Therapy Across Selected Asia-Pacific Markets
DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a Transthyretin Stabilizer for ATTRCM in Australia Singapore South Korea
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
MindWalk Holdings Corp MindWalk NASDAQ HYFT a bionative AI company today launched ReefIQ a HYFTpowered biological context layer for AI drug discovery and biologics development that sits between client discovery data
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
GENESIS Pharma a leading regional biopharma company focused on the commercialization of innovative medicines in Europe today announced the expansion of its longstanding commercial partnership
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Organon NYSE OGN today announced the US Food and Drug Administration FDA approval of the supplemental Biologics License Application sBLA for TOFIDENCE tocilizumabbavi injection for intravenous use a
EventsRead more...
15 - 18
Jun 2026MedTech Summit 2026
JW Marriott Hotel Berlin, Berlin, Germany
15 - 17
Jun 2026Clinical Research 2026
Mercure Hotel MOA Berlin, Germany
16 - 17
Jun 2026LogiPharma Asia 2026
Equarius Hotel, Singapore
16 - 18
Jun 2026CPHI & PMEC China 2026
Shanghai New International Expo Centre (SNIEC), Shanghai, China
16 - 17
Jun 2026PDA Sterile Manufacturing & Regulatory Excellence Summit
Novotel Bangkok on Siam Square, Bangkok, Thailand
18 - 20
Jun 2026CCT 2026
Barcelona, Spain
23 - 24
Jun 2026Supply Chain USA 2026
Chicago, IL
24 - 25
Jun 20266th Edition Drug Safety Symposium 2026
Courtyard by Marriott, Mumbai, India
LATEST NEWSRead more...
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Chiesi Group a researchfocused biopharmaceutical company has completed its acquisition of KalVista Pharmaceuticals KalVista will now operate as part of Chiesis Rare Diseases business unit
Rewrite this news in-house style based on British English without Plagiarism, remove direct speeches, and Use simple and uncomplicated language as far as possible.
Orionis Biosciences has entered into an expanded multiyear collaboration with Novartis to discover and develop molecular glue medicines targeting difficulttotreat diseases across multiple therapeutic areas
PharmaEssentia Secures Taiwan Approval of BESREMi for Essential Thrombocythaemia
PharmaEssentia has received approval from Taiwans Ministry of Health and Welfare MOHW for BESREMi ropeginterferon alfabnjft to treat adult patients with essential thrombocythaemia ET
Antengene Receives China IND Approval for ATG-201 Autoimmune Disease Study
Antengene has received Investigational New Drug IND approval from Chinas National Medical Products Administration NMPA to begin the Phase I ATTRACT study of ATG a CD CD bispecific
Nxera Joins OpenFold AI Research Consortium to Strengthen Drug Discovery Capabilities
Nxera Pharma has joined OpenFold a nonprofit artificial intelligence research consortium focused on developing opensource AI tools for biology and drug discovery
Everest Medicines Enters into Agreement with Vcare PharmaTech for Sumecigrel
Everest Medicines has entered into an exclusive licensing agreement with Vcare PharmaTech for the development registration and commercialisation of Sumecigrel across the AsiaPacific region
